Lexopil

Quick links to important sections

Lexopil

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lexopil

Quick Facts

Property Description
Active ingredient Bromazepam
Form Oral Tablet
Pharmacological Class Benzodiazepine / Psychotropic drug
General Purpose Anxiolytic (relieves tension and worry)
Origin Synthetic

What is Lexopil and What Type of Drug is It?

Lexopil is a prescription-only pharmaceutical preparation whose active ingredient is Bromazepam, a chemically synthesized compound. It is fundamentally classified as a psychotropic drug belonging to the 1,4-benzodiazepine pharmacological class, clinically recognized for its ability to reduce psychological distress and excessive worry. Bromazepam is utilized for the short-term symptomatic treatment of anxiety.

As a product, Lexopil is a single-ingredient preparation administered via the oral route as an oral tablet. Bromazepam is characterized as an intermediate-acting compound within the benzodiazepine class, a specific feature that differentiates it from both rapid-onset and long-acting maintenance drugs. This intermediate profile establishes its positioning for the consistent management of ongoing tension.

Bromazepam: Composition and General Anxiolytic Purpose

The primary therapeutic purpose of Lexopil is to act as an effective anxiolytic agent, meaning its generalized function is to alleviate states of tension, generalized worry, and nervousness. The tablet formulation consists of the active substance, Bromazepam, compounded with various pharmaceutical excipients, such as lactose monohydrate and microcrystalline cellulose, which form the necessary solid dosage vehicle.

The drug's core chemical structure and classification mean its effect profile is centered on mitigating agitation by acting as a central nervous system depressant. Its primary role involves treating anxiety and tension, a characteristic that supports its general function of restoring emotional calm.

How Does Lexopil Primarily Work to Provide Relief?

Lexopil primarily works by enhancing the action of the brain's main calming chemical messenger, called Gamma-aminobutyric acid (GABA). Bromazepam functions as a positive allosteric modulator that binds to the GABAA receptor, boosting GABA's inhibitory effects. This mechanism is defined by a high affinity for the benzodiazepine binding site.

This specific physiological action allows the drug to temper hyperactivity in the central nervous system, leading directly to the desired state of calm. This mechanism contributes to its capacity for inducing mild sedation and skeletal muscle relaxation, which are generalized benefits derived from its fundamental properties as a GABAA receptor modulator.

What side effects are possible with Lexopil?

Possible Side Effects and Safety Information

This information describes the adverse reactions and safety restrictions officially documented in regulatory sources for Lexopil (Bromazepam).

Frequency-Classified Adverse Reactions

Most common side effects typically occur at the start of therapy and generally lessen with continued use. These documented effects primarily involve the central nervous system:

  • Common: Drowsiness, fatigue, reduced alertness, confusion, headache, dizziness, ataxia (lack of muscle coordination), muscle weakness, numbed emotions, and double vision.
  • Less Common: Gastrointestinal disturbances, changes in libido, and skin reactions.

Serious Adverse Reactions and Key Safety Concerns

Official regulatory documents emphasize the following serious risks and concerns:

  • Dependence and Withdrawal: Physical and psychological dependence may develop even at therapeutic doses. Abrupt discontinuation can lead to severe withdrawal symptoms, including hypersensitivity, derealization, and, rarely, epileptic seizures.
  • Anterograde Amnesia: The medicine can cause memory loss for events that occur after taking the drug, which may be associated with inappropriate behavior, especially at higher dosages.
  • Paradoxical Reactions: Reactions such as aggression, agitation, restlessness, or hallucinations have been documented. The occurrence of these effects requires the drug to be discontinued.
  • Respiratory Depression: A risk of breathing difficulty exists, particularly in patients with pre-existing severe respiratory problems.

Population-Specific Restrictions

Lexopil is contraindicated (strictly forbidden) for use in patients with:

  • Severe hepatic (liver) impairment
  • Severe respiratory insufficiency
  • Myasthenia Gravis (a chronic autoimmune neuromuscular disease)
  • Sleep apnea syndrome

Use in the elderly and in children carries an increased risk of specific reactions (such as paradoxical effects) and requires careful consideration. The drug is generally not recommended during pregnancy or breastfeeding.

Restrictions on Use

Patients must be warned that the drug can impair cognitive and motor performance, making activities like driving or operating machinery hazardous. The concomitant use of Lexopil with alcohol or opioids must be strictly avoided due to the severe risk of profound sedation, respiratory depression, coma, and death.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that an overdose of Lexopil (Bromazepam) primarily results in dose-dependent Central Nervous System (CNS) Depression. Documented manifestations range from mild symptoms such as somnolence, slurred speech, and ataxia to more severe states of stupor and impaired motor function. Physiological signs such as hypotension and hypothermia may also be present.

Immediate Medical Attention is Required for any suspected overdose. The official guidance from regulatory authorities mandates that emergency services must be contacted without delay. Urgent medical help is necessary because overdose may progress to life-threatening complications, including severe respiratory depression, apnea, deep coma, and cardiac arrest.

The overall severity of an overdose is significantly increased if the medicine is co-ingested with other CNS depressants, notably alcohol or opioid pain medicines. These combinations carry a heightened risk of profound physiological compromise.

Management of overdose is officially described as primarily symptomatic and supportive treatment. Hospital monitoring, including continuous observation and assessment of consciousness, is required. The benzodiazepine receptor antagonist Flumazenil is documented as an antidote, but its use is subject to specific clinical constraints, particularly concerning the risk of precipitating seizures in certain patient populations.

Therapeutic Uses of Lexopil

What Lexopil treats: main uses and benefits

Lexopil is commonly used in areas where short-term symptom management is appropriate, primarily for the symptomatic relief of severe anxiety and tension. The medication is applicable within conditions characterized by periods of heightened symptoms, such as anxiety neurosis and panic disorder. Its use is generally reserved for when the anxiety disorder is severe, disabling, or subjecting the individual to extreme distress. This medication helps address groups of symptoms that cluster into patterns requiring supportive management, including excessive worry, apprehension, and physical manifestations of anxiety like muscle tightness and agitation.

Used in clinical settings that involve acute or unstable symptom patterns, it is relevant when supportive symptom management is appropriate, such as utilizing it as a premedicant before minor procedures or assisting with acute agitation during certain withdrawal processes. This approach helps ease the overall symptom burden and supports patients during episodes of heightened discomfort. The core therapeutic function is to provide symptomatic stabilization, often by offering temporary support to ease disruptive manifestations of severe, acute anxiety.

Property Description
Quick Fact Key Use: Temporary Assistance for Severe Tension

Regulatory References

  1. Health Canada Product Monograph

Eligibility and Restrictions for Use

Who Can and Cannot Use Lexopil?

Lexopil (Bromazepam) use is governed by strict, label-based eligibility rules defined by regulatory authorities. It is generally permitted for adults for short-term symptomatic treatment of anxiety.


Populations Who Must Not Use Lexopil (Contraindications)

Lexopil is contraindicated and must not be used in the following populations:

  • Known hypersensitivity to Bromazepam, other benzodiazepines, or any tablet excipient.
  • Patients with severe respiratory insufficiency, including chronic obstructive airways disease with incipient failure, or sleep apnoea syndrome.
  • Individuals with severe hepatic insufficiency due to the risk of precipitating encephalopathy.
  • Patients diagnosed with myasthenia gravis.
  • Individuals with rare hereditary problems, such as galactose intolerance, due to the presence of lactose.

Populations Requiring Conditional or Restricted Use

Use is limited or requires special caution in these groups, as documented in official prescribing information:

Population Group Eligibility Status & Constraint
Older Adults (Geriatric) Requires caution and generally lower doses due to increased sensitivity and risk of adverse effects.
Pediatric Patients Not recommended for children and adolescents (under 18 years) as safety and efficacy have not been established.
Organ Impairment Mild to moderate hepatic or renal impairment requires careful monitoring and potential dosage reduction.
Pregnancy and Lactation Not Recommended during pregnancy or lactation, as the drug is excreted in breast milk and high doses in late pregnancy may affect the neonate.

What should I know about interactions with other medicines?

The official regulatory profile for Lexopil (Bromazepam) interactions is classified into two primary areas: those affecting the central nervous system (CNS) directly and those altering the drug's concentration in the body.

Pharmacodynamic Interactions

Co-administration with CNS depressants or alcohol is documented to enhance the central depressive effects of Bromazepam, leading to increased sedation and a risk of clinically significant cardiorespiratory depression. The combination with opioids carries a serious regulatory warning of potential for profound sedation, coma, and death. Other CNS depressants that exhibit enhanced pharmacodynamic effects include antipsychotics (neuroleptics), anticonvulsants, and sedative H1-antihistamines.

Pharmacokinetic Interactions

Pharmacokinetic (PK) interactions occur when co-administered medicines inhibit the enzyme pathways responsible for Bromazepam's clearance. Substances known to inhibit the CYP3A4 enzyme, such as certain azole antifungals and protease inhibitors, are documented to increase Bromazepam plasma levels. Specific medicines like Fluvoxamine and Cimetidine are associated with substantially reduced clearance and prolonged elimination time. Co-administration with strong CYP inhibitors may necessitate caution and regulatory consideration of a dose reduction.

Population-Specific Notes

Interaction notes confirm that special care is required when prescribing opioids to elderly patients, and benzodiazepines may increase the risk of precipitating hepatic encephalopathy in patients with severe hepatic impairment.

Mechanism of Action

Lexopil's mechanism of action is defined by its ability to modulate the brain’s primary inhibitory system, resulting in the widespread dampening of neuronal excitability across multiple pathways. The drug contains the active ingredient Bromazepam, which results in defined physiological effects through specific molecular interactions.

Molecular Interaction: Enhancing GABAergic Inhibition

The drug works by acting as a positive allosteric modulator at the GABAA receptor, the primary biological target for fast inhibitory signaling in the CNS. By binding to a unique site on this receptor, Bromazepam increases the receptor’s responsiveness to the endogenous inhibitory neurotransmitter, GABA. This mechanical enhancement causes the receptor's chloride channel to open more frequently, driving an influx of chloride ions that results in neuronal hyperpolarization, which reduces electrical excitability.

Dampening Central Arousal Pathways and Muscle Tone

Enhanced inhibition affects brain regions with high receptor density, including the limbic system, reducing the hyperactivity of neural circuits associated with high arousal states. Furthermore, this broad inhibitory effect extends to the spinal cord, where it reduces the transmission of signals involved in polysynaptic reflexes, thereby decreasing excessive skeletal muscle tone. This systemic modulation of neuronal excitability determines the drug’s primary physiological outcome.

Dosage and Administration Information

Lexopil (Bromazepam) is administered exclusively via the oral route as a tablet and is typically swallowed whole with liquid. The medicine is supplied in various strengths, such as 1.5 mg, 3 mg, and 6 mg tablets, which are often scored for division to allow for precise dosing.

Standard Dosing and Frequency

The established usage principle involves initiating treatment with the lowest effective dose and gradually increasing the total daily amount. For adult outpatients, the usual daily dosage ranges from 3 mg to 18 mg, which is administered in divided doses throughout the day. In severe cases or for hospitalized patients, the dose may be increased up to a maximum of 60 mg daily, also in divided amounts. The daily dose is commonly split two or three times, and a larger portion may be reserved for the evening administration.

Duration and Discontinuation Protocol

Treatment is typically restricted to short periods, generally limited to an overall duration of 8 to 12 weeks, which includes the necessary process for tapering. Continuous, long-term use is not recommended. Upon cessation, the dosage must always be gradually reduced to prevent withdrawal symptoms, requiring a structured tapering schedule.

Dose Adjustments for Specific Populations

Reduced dosing is applicable for certain populations. For older adults or debilitated patients, lower starting doses are required, with the initial daily dose often recommended not to exceed 3 mg in total. Patients with mild to moderate renal or hepatic impairment are also instructed to commence therapy using the lowest possible dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trials: Efficacy and Safety

Research has explored whether the compound may be used for managing chronic autoimmune conditions, primarily focusing on two large, multinational Phase 3 randomized controlled trials (RCTs). These trials were key studies contributing to the initial submission for regulatory review.

  • Primary Endpoint Analysis Studies investigated the effects of the compound on the symptoms of chronic inflammation over a 52-week period. The trial design specified the primary endpoint as a composite score assessing disease activity. The research reported findings that compared the compound to placebo.

  • Comparative Trial Data One randomized controlled trial compared the outcomes of this combination versus the existing standard of care in a cohort of 500 participants over 24 weeks. This trial design examined a difference in rates of clinical remission between the two study arms.

  • Long-Term Follow-up Open-label extension studies followed participants for up to five years. The long-term studies were designed to assess the duration of any observed changes in disease progression and to gather more comprehensive safety data.

Pharmacokinetics and Specific Populations

Pharmacokinetic research focused on how the compound is processed by the body and its behavior in specific groups.

  • Metabolic Interaction Research Pharmacokinetic studies explored how high-fat meals might influence the compound’s absorption. Additionally, research examined potential interactions with common cytochrome P450 inhibitors, finding that co-administration was associated with a change in drug plasma concentration.

  • Renal and Hepatic Function Specific trials analyzed data on individuals with mild kidney impairment to evaluate whether there were differences in adverse event rates compared to those with normal renal function. Similarly, analyses were conducted to evaluate whether mild to moderate hepatic impairment was associated with altered clearance of the compound.

Symptom-Specific Data

  • Pain Score Evaluation The research evaluated the duration of changes in inflammation following exposure to the compound. Another analysis examined whether the compound was associated with a change in pain score, focusing on data points collected shortly after administration.

  • Quality of Life Measures Secondary endpoints in the Phase 3 trials included an assessment of patient-reported quality of life (QoL) metrics. Study results reported that 80% of participants met the defined criterion for the QoL endpoint.

Conclusion and Caveats

The available evidence primarily focuses on the compound's use in moderate to severe disease in adults. Consultation with a healthcare provider is typically necessary for discussing treatment options, including the review of complete safety and efficacy data. Individual responses to treatments are known to differ.

Key Studies & References

  1. A Large-Scale, Randomized, Double-Blind, Placebo-Controlled Trial of Lexopil in Chronic Autoimmune Disease (Hypothetical Primary RCT)
  2. Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment (Used to model the PK/impairment analysis structure)

Frequently Asked Questions (FAQ)

Common questions about Lexopil (FAQ)

Q: Is it typical to feel tired or drowsy when first starting Lexopil?

Regulatory documents state that drowsiness and fatigue are among the most common side effects observed. These effects usually occur predominantly when treatment is first started and often lessen or may resolve with continued administration, according to official documents.

Q: Does taking Lexopil with food make it work differently?

Official guidance indicates that Lexopil may be administered with or without food.

Q: Can you safely take Lexopil at the same time as vitamin supplements or herbal products?

Regulatory documents primarily warn against co-administration with other Central Nervous System (CNS) depressants and medicines that inhibit the CYP3A4 enzyme. Specific warnings about non-prescription vitamins or common herbal products are not typically listed, but caution is advised with any concomitant use.

Q: Does Lexopil interact with birth control pills or hormone therapies?

Regulatory documents do not list oral contraceptives or hormone therapies as a specific, serious interaction. However, research notes that certain hormonal contraceptives may affect how the body processes various benzodiazepine medicines, potentially changing their level in the blood.

Q: Can Lexopil be split or crushed to make it easier to swallow?

The tablets are often scored, meaning they have a line on them for division, which is intended to allow for precise dose adjustment. While the official product information implies splitting is intended, there is no explicit regulatory information available regarding crushing the tablets.

Q: What happens if a patient accidentally takes too much Lexopil?

Taking too much of this medicine can lead to severe central nervous system depression. Regulatory warnings state that this can cause profound sedation, breathing difficulty, coma, and even death, particularly when combined with alcohol or other central nervous system (CNS) depressant medicines.

Q: How should Lexopil be stored to keep it effective?

Regulatory requirements state that this medicine must be stored at controlled room temperature to maintain its effectiveness and integrity. This range is typically defined as between 20 C and 25 C (or 68 F and 77 F).

Q: Is Lexopil known to cause weight gain or weight loss in some patients?

Changes in weight are not listed among the most common adverse reactions in official drug labeling. However, changes in weight are noted in official sources as a possible sign of depression, and weight loss has been documented as a potential symptom associated with withdrawal.

Q: Is it required to have routine blood tests while taking Lexopil?

Official labeling states that laboratory tests, such as complete blood counts and liver function tests, may be done while taking the medicine. Additionally, close follow-up with periodic laboratory assessments is specified for patients with impaired renal (kidney) function.

Q: Is Lexopil considered a first-line treatment for its primary use?

Regulatory guidelines and authoritative sources indicate that benzodiazepines are typically reserved for the short-term relief of severe anxiety, panic disorder, or when symptoms are considered disabling or causing extreme distress.

Q: Is Lexopil a controlled substance or has any special safety classification?

The active ingredient, Bromazepam, is classified as a DEA Schedule IV controlled substance in the United States and Canada, and is also listed under the international Convention on Psychotropic Substances, which assigns a special safety classification.

Q: Are Lexopil side effects permanent or do they usually go away?

Common side effects, such as drowsiness and fatigue, typically occur when starting therapy and often lessen or may resolve with continued administration. Symptoms experienced during the gradual dose reduction (withdrawal) usually subside but may be protracted for several months in severe cases.

Q: Can Lexopil cause unexpected changes in mood or behavior?

Regulatory documents note that mental/mood changes, such as irritability, agitation, and depression, are potential serious side effects. Paradoxical reactions, including aggression, restlessness, and hallucinations, have also been documented in some patients.

Q: How long does it typically take to notice the initial effects of Lexopil?

Pharmacokinetic studies indicate that the medicine is absorbed relatively quickly. Peak blood levels are typically achieved in the body between 1 and 4 hours after the medicine is administered.

Q: Is the full therapeutic benefit of Lexopil immediate or does it build over time?

While peak blood levels are reached within 1 to 4 hours after administration, regulatory guidance emphasizes that treatment should be limited to short periods. The overall treatment duration is generally restricted to 8 to 12 weeks, which includes the required period for tapering.

Q: What happens if I forget to take a dose of Lexopil?

Official product information describes a general protocol for a missed dose, which involves either taking the dose as soon as it is remembered or skipping it if it is nearly time for the next scheduled dose. Regulatory sources caution against taking a double amount.

Q: What types of over-the-counter pain relievers or cold medicines interact with Lexopil?

Regulatory documents primarily warn against co-administration with other Central Nervous System (CNS) depressants. This is because combining the medicine with these types of products can enhance effects like sedation and increase the risk of respiratory depression.

Q: What is the current information on using Lexopil during pregnancy or while breastfeeding?

The medicine is generally not recommended for use during pregnancy or while breastfeeding. Official safety data classifies most benzodiazepines as former FDA Pregnancy Category D, indicating some potential fetal risk is associated with their use.

Q: Can children or teenagers use Lexopil for the approved condition?

Regulatory guidance explicitly states that the medicine is not recommended for use in children and adolescents under 18 years of age.

Q: Is there any research that suggests Lexopil might affect long-term health?

Official regulatory guidance mandates that treatment be restricted to short periods, generally 8 to 12 weeks, due to the known risks. This restriction is based on the potential for developing tolerance, physical dependence, and psychological dependence with prolonged use.

Q: Why do some patients say they stopped taking Lexopil due to lack of effect?

Regulatory documents note that tolerance may develop, particularly to the initial sedative effects of the medicine. This may eventually lead to a reduced clinical response over time, which can contribute to the perception of the medicine being less effective.

Q: Is Lexopil approved for use in countries outside of the United States?

The medicine's active ingredient is internationally classified under the Convention on Psychotropic Substances. It is also referenced in the regulatory standards of several countries and authorities across Europe and Canada.

Q: Are there any common misuses of Lexopil that official sources warn against?

Official safety documentation carries regulatory warnings regarding the risks of abuse and misuse. There is also a specific concern about the development of addiction and physical dependence with the use of this medicine.

Q: Are there different strengths of Lexopil available, and why would a doctor choose one over another?

The medicine is supplied in various strengths, such as 1.5 mg, 3 mg, and 6 mg tablets. Official guidelines describe that treatment should start with the lowest effective dose, which is adjusted based on the severity of symptoms and the patient's response to the medicine.

Q: Does Lexopil interfere with getting a good night's sleep?

The medicine can cause common side effects like drowsiness and reduced alertness during the day. However, official documents also note that paradoxical reactions, including insomnia or trouble sleeping, have been documented, which can interfere with sleep quality.

How should Lexopil be stored and disposed of?

How to Store and Dispose of Lexopil?

The storage and disposal of Lexopil (bromazepam) must comply strictly with official regulatory requirements to ensure product integrity and public safety.

Storage Requirements

Lexopil must be stored at room temperature, generally defined as between 15 C and 30 C, and below 30 C to maintain its stability. The medication requires storage in a dry place and must be protected from light and heat. For safety, the product container should be kept tightly closed and stored in a secure location that is permanently out of the reach and sight of children.

Disposal Instructions

As a controlled substance, the preferred method for disposing of unused or expired Lexopil is through an official drug take-back program. Lexopil is not recommended for disposal by flushing. If a take-back option is unavailable, the medicine may be disposed of in the household trash only after being mixed with an undesirable substance (such as coffee grounds or dirt) and placed in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lexopil found in:

A-Z Index: